Mrna-1273.251: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Mrna-1273.251: clinical details
Prescribing considerations
- Confirm eligibility and product suitability against current official recommendations.
- Postpone during acute severe febrile illness or acute infection; minor infection or low-grade fever alone need not delay vaccination.
- Assess previous vaccine reactions, allergy to PEG-containing components, anticoagulation, thrombocytopenia, coagulation disorders and capillary leak syndrome history.
- Ensure treatment and supervision for anaphylaxis are immediately available.
- Record the product name and batch number.
Contraindications and cautions
- Hypersensitivity to mRNA-1273.251 or any excipient.
- Severe allergic reaction to an earlier Spikevax vaccination.
Monitoring
- Use observation appropriate to allergy history and local vaccination guidance.
- Take precautions against injury from vasovagal syncope.
- Advise immediate assessment for persistent chest pain, breathlessness or palpitations.
- No routine pharmacokinetic or laboratory monitoring is specified.
Clinical pharmacology
Lipid nanoparticle-encapsulated, non-replicating mRNA encodes a stabilised full-length LP.8.1 SARS-CoV-2 spike protein. Transient local expression induces neutralising antibody and cellular immune responses; conventional pharmacokinetic assessment is not applicable.
Formulation and product differences
- Ready-to-use, white to off-white multidose dispersion for injection.
- The vial has a blue flip-off cap and should be verified as Spikevax LP.8.1 before use.
- Must not be diluted, shaken, refrozen after thawing or mixed with another medicinal product.
- Contains PEG2000-DMG, SM-102, cholesterol, DSPC, trometamol, acetate, sucrose and water for injections.
Mrna-1273.251 interactions
Other vaccines and treatments affecting immunity or bleeding may need practical consideration.
Seasonal inactivated influenza vaccines
May be given at the same visit using separate injection sites.
Recombinant adjuvanted shingles vaccine
May be given at the same visit, although fatigue, muscle aches, chills and fever may occur more often.
Other injectable vaccines
Use a different injection site; product-specific evidence may be limited.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.